Shoreline Biosciences

Shoreline Biosciences, based in San Diego, CA, specializes in innovative cellular immunotherapy solutions, focusing on iPSC-derived natural killer cells and macrophages to provide effective therapies for unmet medical needs. Shoreline Biosciences, founded in 2020 in San Diego, US, is focused on developing cellular immunotherapy solutions. The company has successfully raised a total of USD 140 mn in its latest funding round, Series B, which occurred on October 28, 2021, led by Ally Bridge Group. The CEO is Kleanthis Xanthopoulos, and the company has completed 3 deals so far.

Shoreline Biosciences specializes in innovative cellular immunotherapy solutions, primarily focusing on iPSC-derived natural killer cells (iNK) and macrophages (iMACs). Their core offerings are designed to provide safe, effective, and affordable therapies for patients with unmet medical needs, utilizing advanced techniques in iPSC differentiation, genetic engineering, and immune cell biology. The company's iNK and iMACs platforms facilitate the development of homogeneous and scalable off-the-shelf products, targeting various therapeutic applications such as cancer treatment and immune system enhancement. Shoreline Biosciences serves a diverse client base that includes healthcare providers, biotechnology firms, and research institutions, primarily within North America and Europe, aiming to address critical healthcare challenges through their state-of-the-art therapies.

Shoreline Biosciences generates revenue primarily through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. Transactions typically occur on a B2B basis, involving agreements for the supply of their cellular immunotherapy products for clinical trials, research purposes, or commercial applications. The structure of these transactions may include licensing agreements and service contracts, where clients pay for access to specific therapies or technologies developed by Shoreline. In November 2021, Shoreline Biosciences raised USD 140 mn in venture funding to advance its proprietary iPSC platform for treating blood cancers, solid tumors, and other health conditions.

The company plans to leverage this funding to accelerate the design and launch of new products aimed at addressing critical therapeutic areas. Expanding into international markets, Shoreline aims to increase its presence in Asia and Europe by 2023, targeting collaborations with key healthcare providers and institutions.